Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential dose-finding study of alfentanil ED50 for suppressing movement during ESWL with propofol
ChiCTR2500103313Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alfentanil and propofol in Pancreatic duct stone and choledocholithiasis, sponsored by Hangzhou First People's Hospital. Primary endpoint: Somatic movement response during surgery. Planned start May 2025; status: not yet recruiting.
02
Drugs
alfentanilpropofol
03
Conditions
Pancreatic duct stonecholedocholithiasis
Beyond the preview
Go deeper on ChiCTR2500103313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103313.